Core Viewpoint - The company is entering a production phase for its "1 million tons corn deep processing health food ingredients project," which is expected to impact its revenue and profit structure due to changes in product mix and rising management costs [1] Group 1: Project Updates - The first phase of the "1 million tons corn deep processing health food ingredients project" is entering production, focusing on liquid syrup and some crystalline sugar alcohol products [1] - The second phase of the "200 million tons corn deep processing health food ingredients project" is planned for future development, with various product lines to be constructed at an appropriate time [1] Group 2: Financial Performance - The gross margin has decreased primarily due to changes in the sales product structure caused by the launch of production lines at Zhoushan Huakang [1] - Management expenses are expected to rise in 2024 due to increased employee compensation related to the Zhoushan project and higher stock-based compensation expenses from the company's equity incentive plan [1] Group 3: Growth Drivers - The company's xylitol, crystalline sorbitol, and crystalline maltitol products are leading in market capacity and output, which will continue to be the main sources of revenue and profit [1]

华康股份 2024 年度董事会工作报告 浙江华康药业股份有限公司 2024 年度董事会工作报告 2024 年，公司董事会严格按照《公司法》《公司章程》《上市公司治理准则》 《上海证券交易所股票上市规则》等法律法规以及公司制度的规定，恪尽职守， 切实履行股东大会赋予的各项职责，严格执行股东大会各项决议，勤勉尽责开展 各项工作；积极推进董事会各项决议实施，不断规范公司法人治理结构，保证董 事会科学决策和规范运作。现将公司董事会 2024 年度工作情况汇报如下： 一、2024 年度经营讨论分析 公司以"做世界领先的糖醇专家"为企业愿景，坚持执行"深耕主业、规模 倍增、卓越运营、管理变革"的战略目标和规划，持续筑牢主营业务根基，提升 核心竞争力，稳健发展主营业务。同时积极探索并开拓新产品领域，开拓新的增 长空间，为企业的长远发展注入源源不断的活力。 "200 万吨玉米精深加工健康食品配料项目"分两期建设，其中一期项目 1 华康股份 2024 年度董事会工作报告 "100 万吨玉米精深加工健康食品配料项目"于 2022 年 8 月启动，一期项目建 设期为 5 年，分两个阶段，第一阶段建设期 2 年，主要以液体糖浆类及部 ...